Genmab's Phase 3 EPCORE FL-1 trial subgroup analysis found that epcoritamab combined with rituximab and lenalidomide (R2) delivers sustained efficacy and manageable safety in relapsed or refractory follicular lymphoma patients, regardless of baseline risk factors. The combination improved progression-free survival, overall response rates, and complete response rates across various patient subgroups, including different risk scores and patient fitness levels. These results, presented at the 2026 European Hematology Association Congress, support epcoritamab + R2 as a promising fixed-duration treatment option for this patient group. The safety profile remained consistent with no new concerns, reinforcing its potential to transform treatment for relapsed follicular lymphoma.
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
The US will impose a 25% tariff on most imports from Brazil starting July 22, following a yearlong investigation into alleged unfair trade practices by Brazil. The tariffs target issues such as Brazil's demands on US tech firms to remove political co...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
